Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

221,761-221,790 of 319,975

filter-aware
30
The slide highlights the safety profile of the drug candidate, specifically noting the absence of serious adverse events and the nature of injection site reactions.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
31
MAD = Multiple Ascending Dose. PK = Pharmacokinetics.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
32
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
33
The slide outlines a 28-day treatment schedule with specific administration days highlighted in green.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
34
The slide presents two visualizations: a dot plot with error bars for longitudinal data and a waterfall plot for individual subject response at Day 14.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
35
The slide presents two distinct visualizations: a point-range plot for longitudinal data and a waterfall plot for individual subject response.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
36
The slide highlights that demographics are similar between Phase 1 and Phase 2 trials.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
37
Data presented as n, mean (SD), median, Q1/Q3, and min/max.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
38
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
39
Larimar Therapeutics | Investor Presentation Deck | 44 slidesLarimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
40
Kaplan-Meier survival curve showing efficacy of FXN replacement therapy.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
41
The slide highlights key preclinical efficacy outcomes for the drug candidate CTI-1601.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
42
Includes two charts: a bar chart for hFXN concentration and a dot plot with error bars for SDH activity.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
43
Data shows significant differences (****) between vehicle and CTI-1601 treated KO mice.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
44
The slide uses two line charts to demonstrate efficacy in two different cardiac metrics (Ejection Function and Fractional Shortening) over an 8-week period.Larimar Therapeutics | Investor Presentation Deck | 44 slides · Larimar Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
01
Slide 1
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Attention1 hit
02
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Attention1 hit
03
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Attention1 hit
04
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Need1 hit
05
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
06
The slide outlines a deal structure involving upfront payments, milestones, royalties, and a division of development labor.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · SatisfactionLoop · Hypothesis Test1 hit
07
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
08
The chart shows a stacked bar breakdown of U.S. vs EU sales over 6 quarters.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The slide uses a grid-based layout to organize clinical trials by stage and therapeutic focus.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
10
The slide uses bar charts to compare year-over-year performance, highlighting percentage changes.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
11
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
12
The chart illustrates a net decrease of $2M ($147M to $145M) driven by R&D savings offset by SG&A and Admin increases.Legend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Satisfaction1 hit
13
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Action1 hit
14
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Action1 hit
15
Legend Biotech | Results Presentation Deck | 15 slidesLegend Biotech | Results Presentation Deck | 15 slides · Legend Biotech
Conference presentation Investor relations Beat · Action1 hit